Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
(WorldNews Switzerland)

Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures -- number set to increase substantially over next two decades[2] Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab Holzkirchen, July 22, 2019 - Sandoz, a Novartis division and a global leader in biosimilars, today announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar denosumab. The study aims to confirm that the...